Investors

Press Releases

ObsEva SA Reports Further Infant Follow-up Data from IMPLANT2 Trial Echoing Favorable Safety Profile of Nolasiban in IVF

April 29, 2019

Geneva, Switzerland and Boston, MA – April 29 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of…

Read more

ObsEva SA to Participate in Upcoming Investor Conferences

April 1, 2019

Geneva, Switzerland and Boston, MA – April 1, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

Publication of ObsEva SA Invitation to 2019 Annual General Meeting of Shareholders

March 29, 2019

Geneva, Switzerland and Boston, MA – March 29, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

Nolasiban Set to Revolutionise Fertility: Interview in ‘The Times’ with ObsEva CEO, Ernest Loumaye

March 27, 2019

Read more

ObsEva SA to Present OBE022 Clinical Data for Treatment of Pre-term labor (PTL) at the SRI 66th Annual Scientific Meeting, March 12 -16, 2019

March 13, 2019

Geneva, Switzerland and Boston – March 13, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization of…

Read more

ObsEva Reports Fourth Quarter and Full Year 2018 Financial Results, Provides Business Update

March 5, 2019

Major 2018 Accomplishments Driven by Positive Clinical Trial Results –Significant increase in rates of pregnancy and live birth (up to…

Read more

ObsEva SA to Hold Fourth Quarter and Full Year 2018 Financial Results and Business Update Call on March 5, 2019

February 27, 2019

Geneva, Switzerland and Boston, MA –February 27, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a Swiss clinical-stage biopharmaceutical company focused on the development and…

Read more

ObsEva SA to Participate in Upcoming Investor Conferences

February 22, 2019

Geneva, Switzerland and Boston, MA – February 22, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

Update: ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial

January 23, 2019

Geneva, Switzerland and Boston, MA – January 23, 2019 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more

ObsEva SA Reports Initial Good Safety of OBE022 in Pregnant Women with Preterm Labour and Announces Start of Part B of the PROLONG Trial

January 23, 2019

Geneva, Switzerland and Boston, MA – January 23, 2018 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company focused on the development and commercialization…

Read more
 
 

Sign up for news

 
 

* Type:


InvestorHCPNursePayerHospital PharmacistRetail PharmacistOther












Read our privacy policy here.